Nuplazid

Chemical Namepimavanserin
Dosage FormTablet (oral; 10 mg); Capsule (oral; 34 mg)
Drug ClassAntipsychotics
SystemNervous
CompanyAcadia Pharmaceuticals Inc.
Approval Year2016

Indication

  • To treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease.
Last updated on 10/23/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nuplazid (pimavanserin) Prescribing Information2019ACADIA Pharmaceuticals Inc., San Diego, CA